Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 641–650 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 641
- Medicine slug
- fluvastatin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
0.35 L/kg
- Numeric value
- 0.35
- Unit
- L/kg
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ab4296c-87c2-4c64-b218-d620eef51310 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:726ea2db-f1b0-4b73-a515-02157db88a42 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02db192f-0cdb-4aef-aa6e-cfb9b6cb0101 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0a7247c-5d83-4bc1-840f-c58314d14195 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5e8d1da-8911-42db-9f90-cba04b28d011 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48801d7c-99ac-4a78-b714-299e2a5562ea (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc55110f-1ad6-4f97-840d-62b3a5ac415a (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3565bfd3-ef9f-456d-b4be-a294a7a0f01c (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VDss) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccd6bbe1-e293-4e1c-9ec4-e6c217612e77 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aad8b373-0aec-4efb-8e61-3d8114b31127 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3c9f49c-051c-451a-8749-1a7bee820078 (opens source in a new tab)
Fluvastatin label
Version not recorded · Effective date not recorded
The mean volume of distribution (VD ss ) is estimated at 0.35 L/kg.
Projected row 642
- Medicine slug
- fluvoxamine
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 24
- Source count
- 24
- Agreement rate
- 0.708333
- Recorded readings
53%
- Numeric value
- 53
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddc9e7e8-f041-43bb-970b-cd4b30367637 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47daea9e-545d-4a67-b2b2-d12c3c98734b (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b107225-ed5a-4461-9184-f3f2bad1892f (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:642b7b5e-9f1c-479b-b9b3-bf06774f7b60 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate tablets is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5198b1c8-8dd6-4b8f-bd85-294ac468af53 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:191912e6-b3c8-be1a-e063-6394a90a8dd4 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate tablets is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3d59ca9-dd42-4b1c-bd2d-23eb507598b8 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate tablets is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8320308-084f-43fb-9b1d-5620a0efaf46 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Antagonism of some of these receptors is thought to be associated with various sedative, cardiovascular, anticholinergic, and extrapyramidal effects of some psychotropic drugs. 12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9972efbb-46cd-45b7-b71c-35032311b70c (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35b377d9-5b7a-4d8e-b6c1-4291d02f5dae (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate tablets is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5b2128d-2363-4966-971f-83219755ecd7 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b5207a-d87b-4541-ac6b-aa1c51715fcf (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4239fc32-e5cb-4393-b90c-742db42b5d07 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2df4f9cf-5803-d8ea-e063-6394a90ad855 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate tablets is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eeb14df-6fcf-a737-5359-5744eb4accea (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4e0212a-ce68-4466-a0e4-f87d5d9ff0b3 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ecd83ec-88f5-4f85-9cc2-9068375d8820 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: The absolute bioavailability of fluvoxamine maleate is 53%.
84%
- Numeric value
- 84
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a6836ab-bd0e-410b-82af-07720e386532 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
In the single-dose crossover study, mean C max was 38% lower and relative bioavailability was 84% for fluvoxamine maleate extended-release capsules versus immediate-release fluvoxamine maleate tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4527a684-51c0-1858-e063-6394a90a2631 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
In the single-dose crossover study, mean C max was 38% lower and relative bioavailability was 84% for fluvoxamine maleate extended-release capsules versus immediate-release fluvoxamine maleate tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9924422b-7c90-42bf-a680-ffd92063d5f0 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
In the single-dose crossover study, mean C max was 38% lower and relative bioavailability was 84% for fluvoxamine maleate extended-release capsules versus immediate-release fluvoxamine maleate tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49601858-df61-4522-ac99-0d2892f92e11 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
In the single-dose crossover study, mean C max was 38% lower and relative bioavailability was 84% for fluvoxamine maleate extended-release capsules versus immediate-release fluvoxamine maleate tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5574f41-d4df-42d5-baae-b317fb7c88bf (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
In the single-dose crossover study, mean C max was 38% lower and relative bioavailability was 84% for fluvoxamine maleate extended-release capsules versus immediate-release fluvoxamine maleate tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d492230c-f56a-4759-ba86-7090b9f44063 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
In the single-dose crossover study, mean C max was 38% lower and relative bioavailability was 84% for fluvoxamine maleate extended-release capsules versus immediate-release fluvoxamine maleate tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bbd7e39-b9ab-4716-9522-aa8c4b92210e (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
In the single-dose crossover study, mean C max was 38% lower and relative bioavailability was 84% for fluvoxamine maleate extended-release capsules versus immediate-release fluvoxamine maleate tablets.
Projected row 643
- Medicine slug
- fluvoxamine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 24
- Source count
- 12
- Agreement rate
- 0.583333
- Recorded readings
16.3 hours
- Numeric value
- 16.3
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a6836ab-bd0e-410b-82af-07720e386532 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
After administration of a 100 mg, single oral dose of fluvoxamine maleate extended-release capsules, the mean plasma half-life of fluvoxamine in healthy male and female volunteers was 16.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4527a684-51c0-1858-e063-6394a90a2631 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
After administration of a 100 mg, single oral dose of fluvoxamine maleate extended-release capsules, the mean plasma half-life of fluvoxamine in healthy male and female volunteers was 16.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9924422b-7c90-42bf-a680-ffd92063d5f0 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
After administration of a 100 mg, single oral dose of fluvoxamine maleate extended-release capsules, the mean plasma half-life of fluvoxamine in healthy male and female volunteers was 16.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49601858-df61-4522-ac99-0d2892f92e11 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
After administration of a 100 mg, single oral dose of fluvoxamine maleate extended-release capsules, the mean plasma half-life of fluvoxamine in healthy male and female volunteers was 16.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5574f41-d4df-42d5-baae-b317fb7c88bf (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
After administration of a 100 mg, single oral dose of fluvoxamine maleate extended-release capsules, the mean plasma half-life of fluvoxamine in healthy male and female volunteers was 16.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d492230c-f56a-4759-ba86-7090b9f44063 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
After administration of a 100 mg, single oral dose of fluvoxamine maleate extended-release capsules, the mean plasma half-life of fluvoxamine in healthy male and female volunteers was 16.3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bbd7e39-b9ab-4716-9522-aa8c4b92210e (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
After administration of a 100 mg, single oral dose of fluvoxamine maleate extended-release capsules, the mean plasma half-life of fluvoxamine in healthy male and female volunteers was 16.3 hours.
17.4 hours
- Numeric value
- 17.4
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:642b7b5e-9f1c-479b-b9b3-bf06774f7b60 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
The multiple dose elimination half-life of fluvoxamine was 17.4 hours and 25.9 hours in the elderly compared to 13.6 hours and 15.6 hours in the young subjects at steady state for 50 mg and 100 mg doses, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:191912e6-b3c8-be1a-e063-6394a90a8dd4 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
The multiple dose elimination half-life of fluvoxamine was 17.4 hours and 25.9 hours in the elderly compared to 13.6 hours and 15.6 hours in the young subjects at steady state for 50 mg and 100 mg doses, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3d59ca9-dd42-4b1c-bd2d-23eb507598b8 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
The multiple dose elimination half-life of fluvoxamine was 17.4 hours and 25.9 hours in the elderly compared to 13.6 hours and 15.6 hours in the young subjects at steady state for 50 mg and 100 mg doses, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35b377d9-5b7a-4d8e-b6c1-4291d02f5dae (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
The multiple dose elimination half-life of fluvoxamine was 17.4 hours and 25.9 hours in the elderly compared to 13.6 hours and 15.6 hours in the young subjects at steady state for 50 mg and 100 mg doses, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2df4f9cf-5803-d8ea-e063-6394a90ad855 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
The multiple dose elimination half-life of fluvoxamine was 17.4 hours and 25.9 hours in the elderly compared to 13.6 hours and 15.6 hours in the young subjects at steady state for 50 mg and 100 mg doses, respectively.
Projected row 644
- Medicine slug
- fluvoxamine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 24
- Source count
- 24
- Agreement rate
- 1
- Recorded readings
25 L/kg
- Numeric value
- 25
- Unit
- L/kg
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a6836ab-bd0e-410b-82af-07720e386532 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution/Protein Binding : The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddc9e7e8-f041-43bb-970b-cd4b30367637 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4527a684-51c0-1858-e063-6394a90a2631 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution/Protein Binding: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9924422b-7c90-42bf-a680-ffd92063d5f0 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution/Protein Binding: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47daea9e-545d-4a67-b2b2-d12c3c98734b (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b107225-ed5a-4461-9184-f3f2bad1892f (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:642b7b5e-9f1c-479b-b9b3-bf06774f7b60 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49601858-df61-4522-ac99-0d2892f92e11 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution/Protein Binding: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5198b1c8-8dd6-4b8f-bd85-294ac468af53 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:191912e6-b3c8-be1a-e063-6394a90a8dd4 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3d59ca9-dd42-4b1c-bd2d-23eb507598b8 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8320308-084f-43fb-9b1d-5620a0efaf46 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9972efbb-46cd-45b7-b71c-35032311b70c (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35b377d9-5b7a-4d8e-b6c1-4291d02f5dae (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5b2128d-2363-4966-971f-83219755ecd7 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b5207a-d87b-4541-ac6b-aa1c51715fcf (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4239fc32-e5cb-4393-b90c-742db42b5d07 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2df4f9cf-5803-d8ea-e063-6394a90ad855 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5574f41-d4df-42d5-baae-b317fb7c88bf (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution/Protein Binding: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eeb14df-6fcf-a737-5359-5744eb4accea (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d492230c-f56a-4759-ba86-7090b9f44063 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution/Protein Binding: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4e0212a-ce68-4466-a0e4-f87d5d9ff0b3 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ecd83ec-88f5-4f85-9cc2-9068375d8820 (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bbd7e39-b9ab-4716-9522-aa8c4b92210e (opens source in a new tab)
Fluvoxamine label
Version not recorded · Effective date not recorded
Distribution/Protein Binding: The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
Projected row 645
- Medicine slug
- fomepizole
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
0.6 L/kg
- Numeric value
- 0.6
- Unit
- L/kg
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82dc2920-af7f-4e43-9f6d-8877a71884cd (opens source in a new tab)
Fomepizole label
Version not recorded · Effective date not recorded
The volume of distribution is between 0.6 L/kg and 1.02 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:911312e2-3a7c-4c97-88a8-b8d92cd12923 (opens source in a new tab)
Fomepizole label
Version not recorded · Effective date not recorded
The volume of distribution is between 0.6 L/kg and 1.02 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:256910fe-91f2-48f6-b0b4-55edc52dacd4 (opens source in a new tab)
Fomepizole label
Version not recorded · Effective date not recorded
The volume of distribution is between 0.6 L/kg and 1.02L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a31d0148-2729-49de-b666-f24b0dfd2401 (opens source in a new tab)
Fomepizole label
Version not recorded · Effective date not recorded
The volume of distribution is between 0.6 L/kg and 1.02 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e133194-dacb-446a-a657-2d2430a02373 (opens source in a new tab)
Fomepizole label
Version not recorded · Effective date not recorded
The volume of distribution is between 0.6 L/kg and 1.02 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dea37fd-ec17-416e-b28e-980a87d49e1a (opens source in a new tab)
Fomepizole label
Version not recorded · Effective date not recorded
The volume of distribution is between 0.6 L/kg and 1.02 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fed6052-f159-46d6-8be1-31e18a7ba918 (opens source in a new tab)
Fomepizole label
Version not recorded · Effective date not recorded
The volume of distribution is between 0.6 L/kg and 1.02L/kg.
Projected row 646
- Medicine slug
- fondaparinux
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
100%
- Numeric value
- 100
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e0d7bc-3f49-849b-c77c-98682d1c0d19 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3b30c68-cf45-4b46-8ba6-72090f7ba01a (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baa50757-a927-4d56-a933-5d7798fe6ab0 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58789e3d-e5bc-4c2e-a527-495a252fcecd (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b65f642-87f7-4da5-a9c9-02cd1f8d9d16 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ea61d0d-4403-4d9f-a946-85a459cc0aa0 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dffbf7c9-495e-4a33-ac76-57b52f014fc2 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%).
Projected row 647
- Medicine slug
- fondaparinux
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 0.714286
- Recorded readings
17 to 21 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e0d7bc-3f49-849b-c77c-98682d1c0d19 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
The elimination half-life is 17 to 21 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58789e3d-e5bc-4c2e-a527-495a252fcecd (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
The elimination half-life is 17 to 21 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b65f642-87f7-4da5-a9c9-02cd1f8d9d16 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
The elimination half-life is 17 to 21 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ea61d0d-4403-4d9f-a946-85a459cc0aa0 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
The elimination half-life is 17 to 21 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dffbf7c9-495e-4a33-ac76-57b52f014fc2 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
The elimination half-life is 17 to 21 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa.
17 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3b30c68-cf45-4b46-8ba6-72090f7ba01a (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
The elimination half-life is 17 hours to 21 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baa50757-a927-4d56-a933-5d7798fe6ab0 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
The elimination half-life is 17 hours to 21 hours. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa.
Projected row 648
- Medicine slug
- fondaparinux
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 0.714286
- Recorded readings
7 to 11 L
- Numeric value
- 7
- Unit
- L
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e0d7bc-3f49-849b-c77c-98682d1c0d19 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
Distribution: In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 to 11 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58789e3d-e5bc-4c2e-a527-495a252fcecd (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
Distribution: In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 to 11 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b65f642-87f7-4da5-a9c9-02cd1f8d9d16 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
Distribution In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 to 11 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ea61d0d-4403-4d9f-a946-85a459cc0aa0 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
Distribution: In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 to 11 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dffbf7c9-495e-4a33-ac76-57b52f014fc2 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
Distribution: In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 to 11 L.
7 L
- Numeric value
- 7
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3b30c68-cf45-4b46-8ba6-72090f7ba01a (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
Distribution In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 L to 11 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baa50757-a927-4d56-a933-5d7798fe6ab0 (opens source in a new tab)
Fondaparinux label
Version not recorded · Effective date not recorded
Distribution: In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 L to 11 L.
Projected row 649
- Medicine slug
- formoterol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
7 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9786f3e2-4265-4246-9999-f73cd6b33fc8 (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0796acea-70d6-479f-af48-18723b1efd2a (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c1a6c53-af85-4220-9ce3-2373e0928f7f (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2010b5cb-c277-57dd-ed6b-607cad2c45a4 (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd0dac5d-e58c-46ee-9d28-1a1ef7a6be5e (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35538d89-a984-4335-acdf-85a893f51eee (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44284e8c-0503-48c4-ae71-a0d6b865665d (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:303479a7-80fb-1f6d-e063-6394a90abbda (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:419bc85d-8e24-478b-921e-babfb73e79f3 (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb2fe258-fe2e-47f6-8adf-ca75bf6f90af (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4dbb9620-5731-40d9-8258-2977ecc781c4 (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8f7c5ff-bd3c-4eab-b58a-1e3a478e5879 (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d9bf685-8886-4865-834b-2748af124b79 (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07afdf7e-c480-4806-b469-a6a460522bc0 (opens source in a new tab)
Formoterol label
Version not recorded · Effective date not recorded
Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.
Projected row 650
- Medicine slug
- fosamprenavir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
7.7 hours
- Numeric value
- 7.7
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cd1eead-9fc1-426c-bee8-214ffa7d9dc1 (opens source in a new tab)
Fosamprenavir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of amprenavir is approximately 7.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a1424d8-844c-4e24-9ebd-b2c2b61b61a3 (opens source in a new tab)
Fosamprenavir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of amprenavir is approximately 7.7 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=640Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.